Table 2. EGFR and HER-2 inhibitory activity and selectivity index with anti-proliferation activity of the synthesized compounds (C1-C20).

Compounds	IC50(μM)	IC50(μM)	GI50(μM)	GI50(μM)	SI
	EGFR	HER-2	MDA-MB-453	MCF-7	EGFR/HER-2
C1	21.85 ± 2.03	16.01 ± 1.45	63.4 ± 6.12	10.03 ± 0.91	1.36
C2	2.94 ± 0.26	0.56 ± 0.05	2.20 ± 0.18	4.68 ± 0.42	5.25
C3	4.42 ± 0.35	7.18 ± 0.65	19.9 ± 1.84	5.30 ± 0.49	0.62
C4	59.33 ± 5.58	125.3 ± 10.2	>300	185.4 ± 17.8	0.47
C5	43.58 ± 4.10	86.55 ± 8.05	135.1 ± 11.1	57.2 ± 5.36	0.50
C6	4.49 ± 0.41	0.06 ± 0.004	0.20 ± 0.02	4.95 ± 0.43	74.8
C7	9.45 ± 0.88	62.85 ± 5.67	>300	16.8 ± 0.98	0.15
C8	8.63 ± 0.78	0.45 ± 0.04	1.69 ± 0.15	5.64 ± 0.52	19.2
C9	65.16 ± 5.88	0.37 ± 0.03	1.38 ± 0.12	56.2 ± 5.41	176.1
C10	37.95 ± 3.75	0.08 ± 0.006	0.25 ± 0.02	18.2 ± 1.71	474.4
C11	47.83 ± 4.54	1.90 ± 0.15	11.9 ± 1.05	28.5 ± 2.80	25.2
C12	53.82 ± 5.12	0.84 ± 0.07	5.31 ± 0.48	33.9 ± 3.21	64.1
C13	82.03 ± 7.84	0.80 ± 0.07	3.24 ± 0.30	123.3 ± 11.2	102.5
C14	84.26 ± 7.81	1.23 ± 0.10	9.12 ± 0.89	134.7 ± 11.6	68.5
C15	27.50 ± 2.46	0.29 ± 0.02	0.95 ± 0.08	12.1 ± 1.17	94.8
C16	10.20 ± 0.94	0.13 ± 0.01	0.36 ± 0.03	5.99 ± 0.55	78.5
C17	79.71 ± 7.01	0.21 ± 0.02	0.55 ± 0.02	96.4 ± 9.22	379.6
C18	34.03 ± 3.08	0.96 ± 0.08	8.68 ± 0.84	15.2 ± 1.40	35.4
C19	196.5 ± 18.5	12.04 ± 1.02	33.4 ± 2.95	>300	16.3
C20	28.56 ± 2.52	0.03 ± 0.002	0.15 ± 0.01	11.9 ± 1.06	952.0
Erlotinib	0.03 ± 0.003	0.16 ± 0.01	1.56 ± 0.14	0.08 ± 0.006	0.19
Lapatinib	0.01 ± 0.001	0.01 ± 0.001	0.03 ± 0.002	3.12 ± 0.24	1.00